# PPX, Temozolomide, and Concurrent Radiation for Newly Diagnosed Brain Tumors

> **NCT00763750** · PHASE2 · COMPLETED · sponsor: **howard safran** · enrollment: 25 (actual)

## Conditions studied

- Brain Tumor

## Interventions

- **DRUG:** PPX +TMZ+XRT

## Key facts

- **NCT ID:** NCT00763750
- **Lead sponsor:** howard safran
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2011-06
- **Final completion:** 2012-07
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2020-02-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00763750

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00763750, "PPX, Temozolomide, and Concurrent Radiation for Newly Diagnosed Brain Tumors". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00763750. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*